$p = 0.015$). Patients with baseline [LVGLS] $<6.5\%$ had significantly lower survival rates compared with those with baseline [LVGLS] $\geq 6.5\%$ ($p = 0.017$ by log-rank test) (Figure 1D). From multivariable analysis, baseline [LVGLS] also showed significant additive predictive values for all-cause mortality in addition to the current staging system and response to chemotherapy (Figure 1E).

In conclusion, LVGLS showed a modest but significant correlation with amyloid load and log NT-proBNP. However, despite a modest relationship, LVGLS showed a significant additive prognostic value. This finding suggested that impaired LV strain could be a prognostic factor reflecting more than a simple amyloid load, encompassing overall impact from structural damage due to amyloid protein deposition, cardiotoxicity, and fibrosis. With introduction of new therapeutic options for patients with AL amyloid, LVGLS could be used as an imaging biomarker to improve risk stratification.

Darae Kim, MD, PhD
Jin-Oh Choi, MD, PhD
Kihyun Kim, MD, PhD
Seok Jin Kim, MD, PhD
Jung-Sun Kim, MD, PhD
Eun-Seok Jeon, MD, PhD*

*Division of Cardiology
Department of Medicine
Heart Vascular Stroke Institute
Samsung Medical Center
Sungkyunkwan University School of Medicine
81 Irwon-Ro Gangnam-gu
Seoul 06351
Korea

E-mail: eunseok.jeon@samsung.com

<https://doi.org/10.1016/j.jcmg.2020.12.009>

© 2021 Published by Elsevier on behalf of the American College of Cardiology Foundation

This research was supported by a fund (code: 2019ER690200) by Research of Korea Centers for Disease Control and Prevention. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

REFERENCES

1. Ternacle J, Bodez D, Guellich A, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. *J Am Coll Cardiol Img* 2016;9:126-38.
2. Buss SJ, Emami M, Mereles D, et al. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. *J Am Coll Cardiol* 2012; 60:1067-76.
3. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol* 2012;30:989-95.

4. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. *Am J Hematol* 2005;79: 319-28.

5. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol* 2012;30:4541-9.

Proof-of-Principle Demonstration of Direct Metabolic Imaging Following Myocardial Infarction Using Hyperpolarized ^{13}C CMR

Although ischemic heart disease is a major contributor to global disease burden, there remains scope to improve diagnosis, risk stratification, and management of myocardial ischemia. The recent ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) trial showed that after an average follow-up of 3.2 years, invasive therapy did not reduce major adverse cardiac events compared with optimal medical therapy in patients with stable ischemic heart disease (1). The presence of ischemia invariably leads to alterations in the balance between aerobic and anaerobic metabolism, and therefore, noninvasive detection of these metabolic alterations may lead to improvements in patient care pathways. Although current cardiac magnetic resonance (CMR) techniques are able to assess altered perfusion and scar burden, they cannot directly measure metabolic alterations. In addition, whereas positron emission tomography with ^{18}F -fluorodeoxyglucose allows assessment of glucose uptake, it is unable to report on the metabolic fate of glucose beyond its initial phosphorylation by hexokinase, and so a new approach is required.

The fate of glucose metabolism after glycolysis depends on the prevailing metabolic conditions and thus has the potential to be used diagnostically, with the equilibrium between pyruvate dehydrogenase (PDH) activity and lactate dehydrogenase (LDH) activity indicating the balance between aerobic and anaerobic metabolism (2). The recently demonstrated technique of hyperpolarized cardiac magnetic resonance (hp-CMR) offers the ability to noninvasively monitor PDH and LDH activity (3), and may provide the potential for direct imaging of metabolism in the ischemic heart (Figure 1A). Whereas this potential has been established in animal models (4,5), we present here the first hp-CMR images of pathological human myocardial metabolism in ischemic heart disease.

Studies were approved by the National Research Ethics Committee (17/WM/0200). Hyperpolarized [$1\text{-}^{13}\text{C}$]pyruvate was prepared in a GE SPINlab hyperpolarizer (GE Healthcare, Chicago, Illinois) and administered intravenously (0.1 mmol/kg) (3). Hyperpolarized ^{13}C images were acquired on a Siemens 3T Tim Trio scanner (Siemens Healthineers, Erlangen, Germany) using a cardiac-gated sequence consisting of interleaved spectral-spatial excitations of pyruvate, lactate, and bicarbonate resonances followed by a hybrid-shot spiral (HSS) readout (6). A 2-dimensional implementation of HSS was used in case 1 and encoded 3 short-axis slices (basal, mid, apical) of 20-mm thickness per heartbeat with nominal 10-mm in-plane resolution (flip angles: pyruvate 12° ; lactate/bicarbonate 60°). Imaging was performed over an end-expiration breath-hold started 22 s after injection; all 3 slices were encoded each heartbeat for 1 metabolite, and the 3 metabolites were acquired over 3 subsequent heartbeats in the order pyruvate, bicarbonate, and lactate. Three interleaves were used to acquire the presented data, requiring 9 heartbeats in total. For case 2, a 3-dimensional implementation of HSS was used and encoded a $384 \times 384 \times 120 \text{ mm}^3$ volume with nominal 6-mm in-plane resolution and 3 excitations per heartbeat (flip angles: pyruvate 6° ; lactate/bicarbonate 30°) and 12 excitations per volume. As for the 2-dimensional case, 3 interleaves were used to acquire the presented data, requiring 36 heartbeats in total.

Case 1: A 67-year-old man with type 2 diabetes presented with chest pain, non-ST-segment elevation myocardial infarction (cardiac troponin I 44 ng/l), and electrocardiographic evidence of anterolateral territory ischemia. Coronary angiography revealed disease of the distal left main and proximal left anterior descending coronary arteries with angiographic appearances consistent with a chronic total occlusion of the right coronary artery, which was dominant. CMR and late gadolinium enhancement imaging were undertaken to assess viability and inform revascularization. This demonstrated 2 separate areas of infarction: subendocardial infarction (25% to 50%, intermediate viability, presumed acute) of the mid- and apical anterior and anterolateral walls (4 of 17 segments), and transmural (75% to 100%, nonviable, presumed old) infarction of the inferior septum (2 of 17 segments) (Figure 1B). Hyperpolarized [$1\text{-}^{13}\text{C}$]pyruvate imaging (Figure 1C) was undertaken 5 days following the onset of chest pain and showed an absence of ^{13}C -bicarbonate and [$1\text{-}^{13}\text{C}$]lactate signals in the nonviable inferior septum, but ^{13}C -bicarbonate and [$1\text{-}^{13}\text{C}$]lactate signals were seen in

the anterior wall in the region of the subendocardial infarction, demonstrating ongoing oxidative metabolism in the recently infarcted anterior wall.

Case 2: A 76-year-old woman presented 24 h after a severe episode of chest pain to a regional hospital on the island of Jersey. By this time, anterior Q waves were seen on the electrocardiogram; however, pain persisted and ST-segment elevation was still apparent, so the patient was treated with intravenous thrombolytic therapy and flown to our center with the capability for primary coronary intervention for ongoing management. On arrival, the patient was stable without symptoms; echocardiography revealed an akinetic anterior wall. On day 4 following the first onset of pain, CMR was undertaken to assess anterior wall viability before invasive angiography. Hyperpolarized [$1\text{-}^{13}\text{C}$]pyruvate imaging was also undertaken at this time. Late gadolinium enhancement imaging revealed transmural (75% to 100%, nonviable) infarction in the mid- and apical anterior walls, alongside the mid-anterolateral and mid-apical lateral walls (5 of 17 segments), with significant microvascular obstruction typical of acute infarction (Figure 1D). Hyperpolarized [$1\text{-}^{13}\text{C}$]pyruvate imaging (Figure 1E) showed absent ^{13}C -bicarbonate and [$1\text{-}^{13}\text{C}$]lactate signals in the transmural infarction, but both ^{13}C -bicarbonate and [$1\text{-}^{13}\text{C}$]lactate signals were observed in the inferior lateral walls. Management options were discussed with the patient, and a conservative course of action was pursued in the first instance, with invasive angiography reserved for any recurrence of symptoms.

This is the first report to our knowledge of in vivo imaging of pathological metabolism in the human heart using hp-MRI. These 2 cases show that, whereas nonviable segments with transmural infarction show reduced PDH-mediated aerobic conversion to ^{13}C -bicarbonate, viable segments following subendocardial infarction have preserved ^{13}C -bicarbonate signal. This shows the difference in ongoing oxidative metabolism (the hallmark of viability) that exists between viable (hibernating) and nonviable myocardium. Further studies are now needed to investigate whether such a biomarker could be useful in stratifying those that would benefit from revascularization. Despite the presence of reduced PDH flux in the diabetic heart, previous work has demonstrated the potential for this technique to be applied in the diabetic heart (7). Because the subject in case 1 also had type 2 diabetes, this work further emphasizes the ability of hp-MRI to image metabolism in the diabetic heart.

In addition, we have shown that following hyperpolarized [$1\text{-}^{13}\text{C}$]pyruvate injection, [$1\text{-}^{13}\text{C}$]lactate

signals were absent in the nonviable sections, but were seen in the viable recently infarcted segment in case 1 and in the remote myocardium in case 2. Although this possibly represents residual ischemia in the infarcted segment in case 1, this may also be explained by inflammatory changes. The origin of these $[1-^{13}\text{C}]$ lactate signals requires further clarification.

These results demonstrate the emerging potential for hyperpolarized imaging in ischemic heart disease. The detection of downstream conversion to either bicarbonate or lactate after hyperpolarized $[1-^{13}\text{C}]$ pyruvate injection has the potential to characterize the metabolic state of viable myocardium non-invasively. Because this can be achieved in a single 90-s scan, and in the absence of ionizing radiation, this is an exciting prospect for future cardiovascular research.

Andrew Apps, MD†
Justin Y.C. Lau, PhD†
Jack J.J.J. Miller, DPhil
Andrew Tyler, MChem
Liam A.J. Young, MChem
Andrew J.M. Lewis, DPhil
Gareth Barnes, MD
Claire Trumper, BSc
Stefan Neubauer, MD
Oliver J. Rider, DPhil‡
Damian J. Tyler, PhD‡*

*Oxford Centre for Clinical Magnetic Resonance Research
Division of Cardiovascular Medicine
Radcliffe Department of Medicine
University of Oxford
Oxford OX3 9DU
United Kingdom

E-mail: damian.tyler@dpag.ox.ac.uk

<https://doi.org/10.1016/j.jcmg.2020.12.023>

© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

†Drs. Apps and Lau contributed equally to this work as joint first authors. ‡Drs. Rider and Tyler contributed equally to this work as senior authors. This work was funded by the British Heart Foundation (BHF) grants RG/11/9/28921, FS/17/18/32449 (Dr. Apps), RE/08/004/23915 (Dr. Lewis), FS/14/54/30946 (Dr. Rider), FS/14/17/30634 (Prof. Tyler), and FS/19/18/34252), as well as the National Institute for Health Research Oxford Biomedical Research Centre (Dr. Lau), a Novo Nordisk Postdoctoral Fellowship (Dr. Miller), the Engineering and Physical Sciences Research Council grant EP/L016052/1 (Dr. Tyler), and the Medical Research Council (Dr. Young). All authors would also like to acknowledge the support provided by the OXFORD-BHF Centre for Research Excellence (grant RE/13/1/30181). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank Katy Briggs, Katy Crofts, Paloma Delgado, Matt Wilkins, Claire Church, Laura Rodden, and the Clinical Trials Aseptic Services Unit.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

REFERENCES

1. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. *N Engl J Med* 2020;382:1395-407.
2. Apps A, Lau J, Peterzan M, Neubauer S, Tyler D, Rider O. Hyperpolarised magnetic resonance for in vivo real-time metabolic imaging. *Heart* 2018;104:1484-91.
3. Cunningham CH, Lau JYC, Chen AP, et al. Hyperpolarized ^{13}C metabolic MRI of the human heart: initial experience. *Circ Res* 2016;119:1177-82.
4. Ball DR, Cruickshank R, Carr CA, et al. Metabolic imaging of acute and chronic infarction in the perfused rat heart using hyperpolarised $[1-^{13}\text{C}]$ pyruvate. *NMR Biomed* 2013;26:1441-50.
5. Yoshihara HAI, Bastiaansen JAM, Berthonneche C, Comment A, Schwitter J. An intact small animal model of myocardial ischemia-reperfusion: characterization of metabolic changes by hyperpolarized ^{13}C MR spectroscopy. *Am J Physiol Heart Circ Physiol* 2015;309:H2058-66.
6. Tyler A, Lau JYC, Ball V, et al. A 3D hybrid-shot spiral sequence for hyperpolarized ^{13}C imaging. *Magn Reson Med* 2021;85:790-801.
7. Rider OJ, Apps A, Miller JJJJ, et al. Non-invasive in vivo assessment of cardiac metabolism in the healthy and diabetic human heart using hyperpolarized ^{13}C MRI. *Circ Res* 2020;126:725-36.

LETTERS TO THE EDITOR

Hemodynamic Assessment in the Cardiac Intensive Care Unit

May Echocardiography Solve the Conundrum?

Jentzer et al. (1) performed a retrospective study to investigate the association among bidimensional (2D) echocardiography-derived hemodynamic parameters, Society for Cardiovascular Angiography and Interventions shock stages, and in-hospital mortality in patients admitted to the cardiac intensive care unit (CICU). Interestingly, a 2D-echocardiographic assessment of the hemodynamic status at admission showed to be significantly predictive of in-hospital outcomes. Specifically, after correcting for potential confounders, a reduced stroke volume index ($<35 \text{ ml/m}^2$) and increased left ventricular filling pressures (mitral E/e' ratio >15) were independently associated with 2-fold and 50% increased risk of in-hospital mortality, respectively (1).

Hemodynamic data can be determinant in characterizing the type of shock and guiding patient management in critically ill patients (2). On the contrary, previous observational studies and randomized controlled trials in shock patients did not only fail to show any benefit of invasive hemodynamic assessment, but found in most cases an increased risk of in-hospital mortality. This finding was likely related to the complications of an invasive hemodynamic assessment, which